Advanced fMRI Software for Neuropsychiatry Clinical Trials
Official title: Design and Development of an Advanced Functional MRI Software as Medical Device (SaMD) forClinical Trials and Therapeutic Applications in Neuropsychiatry
Funded at Ceretype Neuromedicine in · NIH-11536933 · Data updated 2026-11-12
A new software platform uses advanced brain imaging to improve how neuropsychiatric treatments are tested in people, aiming to make trials faster, cheaper, and more reliable.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ceretype Neuromedicine in NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | April 3, 2025 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $606,409 |
| NIH project number | 4R44MH136867-02 |
| Project ID | NIH-11536933 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with neuropsychiatric disorders participating in industry-sponsored clinical trials that use MRI-based biomarkers.
✕Less likely to help
Individuals not enrolled in trials or whose conditions do not involve MRI-based biomarker endpoints may not directly benefit.
What this research studies
This project will develop an end-to-end, standardized fMRI platform tailored for industry-sponsored neuropsychiatric trials. It builds on multi-echo fMRI techniques to boost signal quality and reproducibility, enabling clearer evidence of treatment effects. The team will focus on automation, artifact reduction, and robust data processing to support regulatory-ready biomarker evidence from human participants. The goal is to improve target engagement data and statistical power in clinical studies involving neuropsychiatric conditions. If successful, the platform could streamline trial design and accelerate bringing effective therapies to patients.
Why it matters
Potential benefit: If successful, patients could benefit from more reliable trial results and faster access to effective neuropsychiatric therapies.
How similar studies have gone: Previous multi-echo fMRI approaches have demonstrated improved signal quality and power, supporting the potential of this platform.
Where this research is happening
-
Ceretype Neuromedicine in
Cambridge, United States Active
Researchers
- Principal investigator: Stern, Emily — Ceretype Neuromedicine in
- Study coordinator: Stern, Emily
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.